Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential Symposium
Moderna to host an investor event via webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT
CAMBRIDGE, MA / ACCESS Newswire / September 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, which will be held October 23-27 in Madrid, Spain.
The presentation details are as follows:
Presidential Symposium:
LBA1- INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)Session Type/Title: Presidential SymposiumDate & Time: Saturday, October 24, 4:30 PM CEST / 10:30 AM EDTPresenter: Georgina V. Long (Sydney, Australia, NSW)Poster Presentations:
Abstract 3151P: Adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma: results from a phase I studySession Type/Title: Poster - Pancreatic cancerDate & Time: Sunday, October 25, 12:00-12:45 PM CETPresenter: David J. Pinato (London, United Kingdom)Abstract 2550TiP: INTerpath-014: A Phase 3 Study of Adjuvant Intismeran Autogene (Intismeran) Plus Subcutaneous Pembrolizumab (Pembro SC) or Intismeran Monotherapy vs Placebo in Completely Resected High-Risk Stage I NSCLCSession Type/Title: Poster - NSCLC, early stageDate & Time: Monday, October 26, 12:00-12:45 PM CETPresenter: Charu Aggarwal (Philadelphia, United States of America)Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
Moderna Investor Event
Moderna will host a live webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT. The webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.
With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.
Moderna Contacts
Media:
Chris RidleyVice President, Global Head of Communications+1 617-800-3651Chris.Ridley@modernatx.com
Investors:
Lavina TalukdarSenior Vice President & Head of Investor Relations+1 617-209-5834Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS NewswireCOMTEX_493029302/2457/2026-09-21T10:12:06
1.51% $3.06
